2 1. Supplemental Methods

Supplemental Method S1. Prioritization of candidate causal genes for eight identified genomic loci

5 To further explore the causal effects of nine index SNPs in eight genomic loci on severe COVID-19, we performed a prioritization analysis by leveraging the Open Target Genetics (OTG, 6 7 https://genetics.opentargets.org/) tool (1). The OTG tool is a web-access integrative resource that aggregates human GWAS summary statistics, including UK Biobank data and NHGRI-EBI 8 GWAS catalog, and functional genomic data, including protein quantitative trait loci data 9 (pQTLs), expression QTL (eQTL) from eQTL Catalogue, eQTLGen and GTEx, and promoter 10 11 capture hiC (PCHI-C) from 27 different cell types, and DNase I hypersensitive site (DHS)-gene promoter correlation and other datasets from a wide range of cell types and tissues. Based on the 12 Variant2Gene (V2G) algorithm, for the index SNP rs2166172 in 1p22.2, we prioritized BARHL2 13 14 as a candidate causal gene for severe COVID-19. With the highest V2G score, CCHCR1 was highlighted as candidate causal gene for the index SNP rs143334143 in 6p21.33, VSTM2A as 15 candidate causal gene for rs622568 in 7p11.2, OAS1 as candidate causal gene for rs2269899 in 16 12q24.13, DPP9 as candidate causal gene for rs2109069 in 19p13.3, and IFNAR2 as candidate 17 causal gene for rs13050728 in 21q22.11. The index SNP of rs13050728 ($P = 1.91 \times 10^{-11}$) in 18 21q22.11 is highly LD with the reported SNP of rs9976829 ($R^2 = 1$) (2) and rs2236757 ($R^2 = 1$) 19 0.8266) (3). The index SNP of rs2269899 in 12q24.13 ($P = 3.24 \times 10^{-8}$) shows high LD with the 20 reported SNP of rs10735079 ($R^2 = 0.9282$) (3). 21

22

Supplemental Method S2. Combination of GWAS summary statistics with scRNA-seq data
 (dataset #1) by using the MAGMA algorithm

As an independent technical approach to validate genetics-related peripheral immune cells in PBMCs implicated in severe COVID-19 identified from the RolyPoly algorithm, we applied a generalized linear regression (GLR) model in the MAGMA (v1.06,

https://ctg.cncr.nl/software/magma) (4). Conditioning on the 10% most specific genes from the 28 single cell data for each cell type, we examined gene-level genetic associations of severe COVID-29 19-associated immune cell types by adding these variables as covariates for the linear regression 30 model. The specificity of each gene for each cell type was calculated by using the mean gene 31 expression of cell type divided the sum of mean gene expression across all cell types. A window 32 33 of 50 kb upstream to 50 kb downstream for a given gene coordinates was set to calculate genelevel association statistics. The 1,000 Genome Project European Phase 3 panel (5) was used as the 34 reference panel for both methods. We restricted the GLR analysis to SNPs in the autosomes, and 35 any SNPs with minor allele frequency < 5% were excluded. The major histocompatibility 36 complex region (Chr6: 25-35 Mbp) was also excluded due to the extensive linkage disequilibrium 37 (LD) in this region. 38 39 40

- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49

51 2. Supplemental Figures

- 53 Supplemental Figure S1. UMP projections of cells in PBMCs from normal controls, mild,
- 54 moderate, and severe COVID-19 patients by using the Seurat R package (dataset #1). Dark
- 55 green represents normal controls, light green represents mild patients, orange represents moderate
- 56 patients, and red represents severe patients.





69 each cell type in PBMCs. Color legend represents the expression level of each marker gene.



- 86 Supplemental Figure S3. Single-cell transcriptomes of PBMCs from normal controls, mild,
- 87 moderate, and severe COVID-19 patients. A) UMAP projections of 514,400 cells from normal
- controls, mild, moderate, and severe patients colored by annotated cell types. There was 13
- 89 clusters with 13 distinct cell types annotated by using well-known markers. B) Normalized
- 90 expression of marker genes on a UMAP plot. For example, the well-known markers of CD14,
- 91 NKG7, PRF1, GNLY, GZMB, LEF1, CD4, CD8A, GZMK, FCGR3A, and NR4A1. C)
- 92 Proportion of cell types among normal controls, mild, moderate, and severe patients. D) Violin
- plots of selected markers (lower row) for 13 cell subpopulations. The left column shows the cell
- 94 types annotated by combinations of markers.



95

96 97

- 99 100
- 101

Supplemental Figure S4. Hierarchical clustering using the PCC of a normalized
 transcriptome between diseases (normal and patients with different COVID-19 severities) in
 cell type resolution (n = 13). The color intensity of the heatmap represents the PPC values. The

color bars above the heatmap shows the disease group and cell type. This analysis was based on the largest scRNA-seq dataset of dataset #1 (accession number: E-MTAB-9357).



- 119 Supplemental Figure S5. Boxplots showing percentages of each cell type for PBMCs in
- 120 donors from healthy control and COVID-19 patients with different severities based on the
- 121 **combined dataset.** The statistical analysis for calculating difference among different groups was
- 122 based on the Wilcoxon sum-rank test.



- 125 Supplemental Figure S6. Regional association plots for severe COVID-19-associated genetic
- 126 **loci based on meta-GWAS summary data.** A-F) 1p22.2, 6p21.33, 7p11.2, 12q24.13, 19p13.3
- and 21q22.11. The purple diamond marks the most strongly associated SNP in each locus with
- severe COVID-19. The color illustrates LD information with the given SNP, as shown in the
- color legend. The detailed information is shown in Supplemental Table S3.



Supplemental Figure S7. Regional association plots for severe COVID-19-associated genetic loci based on meta-GWAS summary data. A-B) Two independent genetic association signals in the 3p21.31 loci (rs35081325, P = 3.32×10^{-58} , and rs33998492, P = 3.59×10^{-14} , respectively). The purple diamond marks the most strongly associated SNP in each locus with severe COVID-19. The color illustrates LD information with the given SNP, as shown in the color legend. C) The results of calculating the LD information between rs35081325 and rs33998492 using the LDpair

140 Tool based on the European population (EUR+TSI). D) Regional association plot for the 9q34.2

141 locus associated with severe COVID-19.



143

- 144
- 145
- 146
- 147
- 148

149 Supplemental Figure S8. Circus plot showing the results of MAGMA-based gene-level association analysis. A for lung tissue, and B for blood. The inner ring demonstrates the 22 150 autosomal chromosomes (Chr1-22) and X chromosome. In the outer ring, a circular symbol stands 151 for a specific gene, and color marks the significant level of the gene. Red color marks genes 152 significantly associated with severe COVID-19 with FDR < 0.05, orange color indicates genes 153 suggestively associated with severe COVID-19 with $6.96 \times 10^{-5} \le P < 0.001$, light blue color marks 154 suggestive genes with $0.001 \le P < 0.05$, and dark blue indicates genes have non-significant 155 associations (P > 0.05). 156



Supplemental Figure S9. The 19 biological pathways enriched from the MAGMA-based pathway enrichment analysis. A) Barplot showing the 19 biological pathways based on the KEGG pathway. B) Multidimensional scaling plot for clustering the 19 biological pathways based on their Jaccard distance (see the Methods). Color represents gene number in each pathway, and circular ring size indicates the Z score of enrichment for each pathway. The detailed information is shown in Supplemental Table S5.



187 Supplemental Figure S10. High consistence results between MAGMA and S-MultiXcan

- analysis. A) Venn diagram exhibiting the overlapped significant genes between MAGMA and S-
- 189 MultiXcan analysis. B) Correlation of significant risk genes identified frim MAGMA and S-
- 190 MultiXcan analysis.



207 Supplemental Figure S11. In silico permutation analysis of 100,000 times of random

- selections. A) The comparison of the top-ranked genes from MAGMA gene-based analysis (P <
- 0.05) with that from S-MultiXcan-based analysis (P < 0.05). B) The comparison of the top-ranked
- 210 genes from MAGMA gene-based analysis (P < 0.05) with that from S-PrediXcan-based analysis
- based on lung tissue (P < 0.05). C) The comparison of the top-ranked genes from MAGMA gene-
- 212 based analysis (P < 0.05) with that from S-PrediXcan-based analysis based on blood tissue (P < 0.05)
- 213 0.05).

214

215

216

217

218



220 Supplemental Figure S12. Multiple independent approaches identify genetics-relevant risk

221 genes associated with severe COVID-19. A) Venn diagram showing the overlapped genes

among SNP-level association analysis, MAGMA gene-based analysis, S-MultiXcan analysis, and

S-PrediXcan analysis based on lung and blood. B) Summary of total 34 genetically risk genes
 associated with severe COVID-19.



Supplemental Figure S13. The 10 biological pathways significantly enriched by 34 risk
genes based on the KEGG database. A) Barplot showing these 10 biological pathways
associated with severe COVID-19. The Arabic numeral in each bar represents the ID of each
pathway ordered by the significant level (Supplemental Table S10). B) Multidimensional scaling
plot for clustering these 10 pathways based on the Jaccard distance (see Methods). Color
represents the significance of each pathway (red color marks the significant pathways with lowest
P values).



Page 15 of 48

- Supplemental Figure S14. Plot of gene-drug interaction analysis for 34 risk genes. The gene-
- drug information was downloaded from the STITCH database (<u>http://stitch.embl.de/</u>). The orange node represents the risk gene, and the light green color stands for the targeted drugs. For more
- detail information, see the method for gene-drug interaction analysis.



276 Supplemental Figure S15. Genetics-risk genes influenced three immune cell subsets for

- severe COVID-19. A) Plot showing the specific genes expressed in three identified immune cell
- subsets for severe COVID-19. The most specificity gene for each cell type is *CCR1* for
- 279 CD16+monocytes, *CXCR6* for memory CD8+T cells, and *ABO* for megakaryocytes. B) Dot plot
- showing the expressed percent of three risk genes of CXCR6, CCR1, and ABO in each peripheral
- cell type in PBMCs among severe patients based on the scRNA-seq dataset #1 (E-MTAB-9357).
- 282 Dot size represents fraction of cells within cell type expressing a given gene, and color intensity
- represents binned count-based expression amounts (log(scaled UMI +1)) among expressing cells.

- 298 Supplemental Figure S16. Dot plot showing the expressed percent of three risk genes of
- *CXCR6*, *CCR1*, and *ABO* in each peripheral cell type in PBMCs among severe patients
- 300 based on two scRNA-seq dataset of #2 (GSE149689) and #3 (GSE150861). Dot size represents
- fraction of cells within cell type expressing a given gene, and color intensity represents binned
 count-based expression amounts (log(scaled UMI +1)) among expressing cells.

315 Supplemental Figure S17. *CCR1*⁺ CD16+monocytes showing higher risk to cytokine storms

among COVID-19 patients. A) Boxplot showing the difference of pathway activity score of both
 cytokine-cytokine receptor interaction and chemokine signaling pathway between *CCR1*⁺ and

- 319 significance. B)-C) Barplot showing the proportion of significant druggable proteins (B) and
- 320 significant druggable proteins associated with COVID-19 (C) between *CCR1*⁺ and *CCR1*⁻
- 321 CD16+monocytes. The hypergeometric test was applied to calculate the significance. D) Venn
- 322 plot exhibiting the overlapped up-DEGs between pairwise comparisons of mild vs. normal,
- 323 moderate vs. normal, and severe vs. normal. E) Functional enrichment analysis based on GO
- biological process for 190 up-DEGs. F) Gene-drug interaction analysis for 190 up-DEGs. G)-L)
- Representative up-DEGs among *CCR1*⁺ CD16+monocytes showing significantly elevated
- expressions with increased COVID-19 severities. G) IRF3, H) CXCL8, I) CD14, J) S100A12, K)
- 327 *IFI6*, and L) *IGSF6*.

329 Supplemental Figure S18. *ABO*⁺ megakaryocytes contribute higher risk to cytokine storms among

330 severe COVID-19 patients. A)-B) Boxplot showing the difference of inflammatory cytokine score (A) and 331 pathway active score (B) between ABO⁺ and ABO⁻ megakaryocytes. There were two pathways of cytokine-cytokine

- receptor interaction and chemokine signaling pathway used. Two-side Wilcoxon test was applied. C) Volcano plot
- 333 showing differentially expressed genes between *ABO*⁺ and *ABO*⁻ megakaryocytes. There were 424 highly-expressed
- 334 genes among *ABO*⁺ megakaryocytes compared with *ABO*⁻ cells. D) Pathway enrichment analysis of 424 highly-
- expressed genes based on the KEGG resource. E) Barplot exhibiting the proportion of *ABO*⁺ megakaryocytes among
- normal controls, mild, moderate, and severe COVID-19 patients. F) Barplot showing the differentially up-DEGs from
- the pairwise comparisons of normal controls with different COVID-19 severities. Venn plot on the top of bar
- showing the overlapped up-DEGs between moderate and severe patients. G) Heatmap showing the up-DEGs from the
 pairwise comparisons. F) Gene-drug interaction analysis for 35 up-DEGs. I)-N) Representative up-DEGs among
- ABO^+ megakaryocytes showing significantly elevated expressions with increased COVID-19 severities.

- 341
- 342

Supplemental Figure S19. Evidence showing the multi-functionality of *CXCR6*⁺ memory CD8+T cells for severe COVID-19. A)-C) Boxplots showing the difference of inflammatory score (A), proliferation score (B), and migration score (C) between *CXCR6*⁺ and *CXCR6*⁻ memory CD8+T cells.

- 346 Two-side Wilcoxon sum-rank test was used. D) Pathway enrichment analysis of 158 highly-expressed
- 347 genes based on the KEGG resource. E)-F) Boxplots showing the cytotoxicity score (E) and exhaustion
- 348 score (F) of among normal, mild, moderate, and severe groups. G)-N) Representative up-DEGs among
- *CXCR6*⁺ memory CD8+T cells showing significantly elevated expressions with increased COVID-19
- 350 severities. G) TCF7, H) HELB, I) COPS6, J) PSMB6, K) PUF60, L) RAB5IF, M) NDUFAF3, and N)
- *HLA-DPB1*.

- the differential number of cellular interactions. Red rectangle marks the elevated interactions of
- both $CCR1^+$ CD16+monocytes and $CXCR6^+$ memory CD8+T cells with other immune cells in
- 362 PBMCs.

- number of cellular interactions between pairwise cell types in BALFs. B) The increased percent
- of cellular interactions of $CCR1^+$ CD16+monocytes with epithelial cells compared with $CCR1^-$
- 380 CD16+monocytes. C) The increased percent of cellular interactions of *CXCR6*⁺ memory CD8+T
- cells with epithelial cells compared with *CXCR6*⁻ memory CD8+T cells.
- 382

392 **3.** Supplemental Tables

Supplemental Table S1. Samples collected from four independent scRNA-seq datasets on COVID-19

Characteristics	Dataset #1 (E-	Dataset #2	Dataset #3	Dataset #4	Total
	MTAB-9357)	(GSE149689)	(GSE150861)	(GSE158055)	samples
Normal controls	16	4	0	0	20
Mild COVID-19	96	5	0	0	101
Moderate COVID-19	106	0	0	3	109
Severe COVID-19	52	6	3	9	70
Remission	0	0	4	0	4

395

396 Supplemental Table S2. Selected well-known markers used to define cell types in PBMCs

Cell types	Markers
CD14+ monocytes	CD14, CD4, NR4A1
CD16+ monocytes	FCGR3A, CX3CR1, CD16, CD4, NR4A1
Na ïve CD4+T cells	LEF1, CD197, TCF7, CD3D, CD3E, CD4
Na ïve CD8+T cells	LEF1, CD197, TCF7, CD3D, CD3E, CD8A
Effector CD4+T cells	PRDM1, PRF1, GZMB, GNLY, CD3D, CD3E, CD4
Effector CD8+T cells	PRDM1, PRF1, GZMB, GNLY, CD3D, CD3E, CD8A
Memory CD4+T cells	GZMK, CD69, AQP3, CD3D, CD3E, CD4
Memory CD8+T cells	GZMK, CD69, AQP3, CD3D, CD3E, CD8A
Exhaustion CD4+T cells	LAG3, TIGIT, CD279,PDCD1, TIM3, CD3D, CD3E, CD4
Exhaustion CD8+T cells	LAG3, TIGIT, CD279, PDCD1, TIM3, CD3D, CD3E, CD8A
Proliferating CD4+T cells	MK167, TYMS, CD3D, CD3E, CD4
Proliferating CD8+T cells	MK167, TYMS, CD3D, CD3E, CD8A
Regulatory CD4+T cells	FOXP3, CD3D, CD3E, CD4
Regulatory CD8+T cells	FOXP3, CD3D, CD3E, CD8A
NK	FCGR3A, CD16, TRGC1, NKG7,NCAM1,CD38,CD62L,GZMB,CD56
В	CD79A, MS4A1, CD19
Plasma B	CD79A, CD38
Na ïve B	IGHD, FCER2
mDC	CD14, CD1C
pDC	CLEC4A, CD123
Megakaryocyte	РРВР
Progenitor	CD34, CD38
DC	FCER1A, IL3RA, CD1C, CD141

397

Supplemental Table S3. Significant SNPs associated with severe COVID-19 identified by meta-GWAS analysis

SNP	CHR	POS	Loci	ATL	OR (95% CI)	Meta P-value
rs35081325	3	45489921	3p21.31	Т	1.81 (1.788-1.853)	3.32E-58
rs2109069	19	4319443	19p13.3	А	1.183 (1.175-1.191)	6.40E-13
rs13050728	21	34215210	21q22.11	С	0.858 (0.851-0.865)	1.914E-11
rs143334143	6	30721426	6p21.33	А	1.273 (1.241-1.273)	1.283E-10
rs505922	9	135749229	9q34.2	Т	0.88 (0.875-0.886)	2.24E-09
rs622568	7	54247894	7p11.2	С	1.167 (1.158-1.175)	2.57E-08
rs2166172	1	90808514	1p22.2	С	1.132 (1.126-1.137)	2.74E-08
rs2269899	12	112981956	12q24.13	Т	1.132 (1.127-1.138)	3.24E-08

400 **Note:** SNP =single nucleotide polymorphism, CHR = chromosome, POS = position, ATL =

401 altered allele, OR = odds ratio, 95% CI = 95% confidence interval, Meta P-value is generated

from the Metal tool by meta-analyzing 969,689 samples from 21 independent contributing

403 studies.

404

Supplemental Table S4. Significant genes associated with severe COVID-19 identified by MAGMA gene-based association analysis

Gene name	CHR	Start POS	Stop POS	Number of SNPs	Z score	P value	FDR
LZTFL1	3	45844808	45977216	314	13.14	1.01E-39	1.93E-35
FYCO1	3	45939391	46057316	331	11.15	3.67E-29	3.51E-25
XCR1	3	46042291	46088979	165	10.28	4.36E-25	2.78E-21
CXCR6	3	45964973	46009845	120	9.91	1.86E-23	8.90E-20
CCR9	3	45907996	45964667	152	9.19	2.01E-20	7.69E-17
SLC6A20	3	45776941	45858039	208	7.33	1.19E-13	3.80E-10
CCR3	3	46263872	46328197	214	7.19	3.35E-13	9.16E-10
CCR1	3	46223200	46269832	177	7.00	1.30E-12	3.11E-09
IFNAR2	21	34582231	34656831	221	6.83	4.21E-12	8.95E-09
CCR2	3	46375235	46422413	136	6.53	3.26E-11	6.24E-08
CCR5	3	46391633	46437697	133	5.69	6.28E-09	1.01E-05
OAS3	12	113356249	113431056	265	5.69	6.35E-09	1.01E-05
OAS1	12	113324739	113377712	157	5.28	6.57E-08	9.67E-05
SPPL2C	17	43902256	43944438	281	4.63	1.81E-06	2.47E-03

CRHR1	17	43677710	43933194	1203	4.59	2.24E-06	2.86E-03
STH	17	44056616	44097060	225	4.57	2.43E-06	2.91E-03
MAPT	17	43951702	44125700	901	4.41	5.09E-06	5.73E-03
UBE2D1	10	60074739	60150513	188	4.40	5.44E-06	5.78E-03
KANSL1	17	44087282	44322740	941	4.20	1.35E-05	1.36E-02
TFAM	10	60124903	60178990	145	4.02	2.94E-05	2.81E-02
CCRL2	3	46428721	46474488	195	3.99	3.33E-05	3.03E-02
IBA57	1	228333429	228389958	118	3.98	3.52E-05	3.06E-02
IL10RB	21	34618665	34689539	230	3.92	4.36E-05	3.63E-02
COX10	17	13952719	14131996	549	3.87	5.37E-05	4.28E-02
NCR2	6	41283528	41338625	328	3.83	6.32E-05	4.84E-02

407 **Note:** SNP =single nucleotide polymorphism, CHR = chromosome, POS = position, FDR = False

408 discovery rate.

409

410 Supplemental Table S5. Significant enriched pathways associated with severe COVID-19

411	identified from MAGMA-based pathway enrichm	ent analysis
-----	---	--------------

ID	KEGG ID	Pathway names	Number of genes	Beta	SE	P value
1	hsa00533	Glycosaminoglycan biosynthesis - keratan sulfate	14	0.66	0.20	5.84E-04
2	hsa05168	Herpes simplex virus 1 infection	183	0.16	0.06	2.13E-03
3	hsa00601	Glycosphingolipid biosynthesis - lacto and neolacto series	27	0.43	0.15	2.69E-03
4	hsa04390	Hippo signaling pathway	153	0.17	0.06	2.87E-03
5	hsa05162	Measles	131	0.19	0.07	3.13E-03
6	hsa05164	Influenza A	167	0.15	0.06	6.36E-03
7	hsa04064	NF-kappa B signaling pathway	92	0.19	0.08	9.44E-03
8	hsa04621	NOD-like receptor signaling pathway	167	0.13	0.06	1.11E-02
9	hsa04625	C-type lectin receptor signaling pathway	104	0.16	0.07	1.13E-02
10	hsa05143	African trypanosomiasis	34	0.28	0.12	1.33E-02
11	hsa05160	Hepatitis C	131	0.14	0.07	1.63E-02
12	hsa04392	Hippo signaling pathway - multiple species	28	0.28	0.13	1.80E-02
13	hsa00603	Glycosphingolipid biosynthesis - globo and isoglobo series	15	0.48	0.23	1.81E-02
14	hsa04137	Mitophagy - animal	64	0.17	0.08	1.87E-02
15	hsa04630	JAK-STAT signaling pathway	158	0.12	0.07	3.50E-02
16	hsa04668	TNF signaling pathway	110	0.13	0.07	3.95E-02

17	hsa00471	D-Glutamine and D-glutamate metabolism	5	0.57	0.34	4.47E-02
18	hsa04060	Cytokine-cytokine receptor interaction	286	0.09	0.05	4.67E-02
19	hsa05132	Salmonella infection	81	0.14	0.09	4.92E-02

⁴¹²

Supplemental Table S6. The 16 significant genes associated with severe COVID-19identified 413

by S-MultiXcan analysis based on 49 tissues from GTEx consortium 414

Gene name	CHR	START	STOP	P value	FDR
LZTFL1	chr3	45864808	45957216	1.08E-30	2.41E-26
SLC6A20	chr3	45796941	45838039	2.19E-29	2.44E-25
CCR9	chr3	45927996	45944667	4.16E-29	3.10E-25
CXCR6	chr3	45984973	45989845	1.56E-28	8.71E-25
XCR1	chr3	46062291	46068979	4.20E-16	1.88E-12
FYCO1	chr3	45959391	46037316	1.53E-14	5.69E-11
CCR3	chr3	46283872	46308197	8.15E-13	2.60E-09
CCR1	chr3	46243200	46249832	1.13E-11	3.15E-08
DNAH3	chr16	20944476	21170762	4.44E-10	1.10E-06
CCR2	chr3	46395235	46402413	1.16E-09	2.59E-06
ABO	chr9	136130563	136150630	1.36E-07	2.76E-04
IFNAR2	chr21	34602231	34636831	3.28E-07	6.10E-04
IL10RB	chr21	34638665	34669539	8.28E-07	1.42E-03
CCR5	chr3	46411633	46417697	1.22E-06	1.95E-03
OAS3	chr12	113376249	113411056	2.83E-06	4.21E-03
CCRL2	chr3	46448721	46454488	4.61E-06	6.43E-03

415

Note: CHR = chromosome, START = start position on chromosome, STOP = stop position on

chromosome, FDR = False discovery rate. 416

417

Supplemental Table S7. The eight significant genes associated with severe COVID-19 418 identified by S-PrediXcan analysis based on lung and blood tissues

Gene name	CHR	START	STOP	Z score	P value	FDR	Tissue
CCR9	chr3	45927996	45944667	11.69	1.47E-31	1.79E-27	Blood
PGLS	chr19	17622278	17632097	-4.64	3.43E-06	2.09E-02	Blood
CXCR6	chr3	45984973	45989845	-10.55	5.10E-26	7.41E-22	Lung

CCR5	chr3	46411633	46417697	-5.46	4.85E-08	3.52E-04	Lung
FOXP4	chr6	41514164	41570122	4.88	1.08E-06	5.23E-03	Lung
IL10RB	chr21	34638665	34669539	4.74	2.19E-06	7.95E-03	Lung
FYCO1	chr3	45959391	46037316	4.65	3.35E-06	8.45E-03	Lung
ABO	chr9	136130563	136150630	4.64	3.49E-06	8.45E-03	Lung

420 **Note:** CHR = chromosome, START = start position on chromosome, STOP = stop position on

421 chromosome, FDR = False discovery rate.

422

423 Supplemental Table S8. The biological pathways enriched by 34 risk genes associated with 424 severe COVID-19

ID	KEGG ID	Pathway names	Number of genes	Ratio	P Value	FDR
		Cytokine-cytokine receptor				
1	hsa04060	interaction	294	10.89	3.89E-08	1.27E-05
		Chemokine signaling				
2	hsa04062	pathway	189	13.17	5.12E-07	8.35E-05
3	hsa05160	Hepatitis C	131	10.86	4.29E-04	3.60E-02
4	hsa05162	Measles	132	10.78	4.42E-04	3.60E-02
		NOD-like receptor signaling				
5	hsa04621	pathway	168	8.47	1.10E-03	6.36E-02
6	hsa05164	Influenza A	171	8.32	1.17E-03	6.36E-02
7	hsa05168	Herpes simplex infection	185	7.69	1.57E-03	6.51E-02
		Kaposi sarcoma-associated				
8	hsa05167	herpesvirus infection	186	7.65	1.60E-03	6.51E-02
9	hsa05169	Epstein-Barr virus infection	201	7.08	2.13E-03	0.077
		Human cytomegalovirus				
10	hsa05163	infection	225	6.32	3.20E-03	0.104

425

426

427

Supplemental Table S9. The percentage of three severe COVID-19-risk genes expressed in all 13 distinct cell types in PBMCs

Cell types	CXCR6	CCR1	ABO
Effector CD8+T cells	0.007	0.008	0.002

Memory CD8+T cells	0.021	0.014	0.004
Naive CD8+T cells	0.013	0.01	0.003
Naive CD4+T cells	3.08E-04	0.001	0.012
Memory CD4+T cells	0.004	0.002	0.014
CD14+ monocytes	8.84E-05	0.099	0.002
CD16+ monocytes	2.42E-04	0.079	0.002
NK	3.19E-03	0.012	0.001
Naive B cells	3.27E-04	0.004	0.007
Dendritic cells	1.63E-04	0.051	0.007
Megakaryocytes	1.64E-03	0.004	0.112
CD34+Progenitors	1.17E-03	0.011	0.039
Mature B cells	0	0.024	0

429

430

Supplemental Table S10. Summary of inflammatory and cytokine-related genes and genes in two identified KEGG pathways

Categories	Gene lists	Resources
Inflammatory-related	ABCA1, ABI1, ACVR1B, ACVR2A, ADGRE1, ADM, ADORA2B, ADRM1, AHR,	PMID: 33657410
-	APLNR, AQP9, ATP2A2, ATP2B1, ATP2C1, AXL, BDKRB1, BEST1, BST2,	
genes	BTG2, C3AR1, C5AR1, CALCRL, CCL17, CCL2, CCL20, CCL22, CCL24,	
	CCL5, CCL7, CCR7, CCRL2, CD14, CD40, CD48, CD55, CD69, CD70, CD82,	
	CDKN1A, CHST2, CLEC5A, CMKLR1, CSF1, CSF3, CSF3R, CX3CL1,	
	CXCL10, CXCL11, CXCL6, CXCL8, CXCL9, CXCR6, CYBB, DCBLD2, EBI3,	
	EDN1, EIF2AK2, EMP3, EREG, F3, FFAR2, FPR1, FZD5, GABBR1, GCH1,	
	GNA15, GNAI3, GP1BA, GPC3, GPR132, GPR183, HAS2, HBEGF, HIF1A,	
	HPN, HRH1, ICAM1, ICAM4, ICOSLG, IFITM1, IFNAR1, IFNGR2, IL10,	
	IL10RA, IL12B, IL15, IL15RA, IL18, IL18R1, IL18RAP, IL1A, IL1B, IL1R1,	
	IL2RB, IL4R, IL6, IL7R, INHBA, IRAK2, IRF1, IRF7, ITGA5, ITGB3, ITGB8,	
	KCNA3, KCNJ2, KCNMB2, KIF1B, KLF6, LAMP3, LCK, LCP2, LDLR, LIF,	
	LPAR1, LTA, LY6E, LYN, MARCO, MEFV, MEP1A, MET, MMP14, MSR1,	
	MXD1, MYC, NAMPT, NDP, NFKB1, NFKBIA, NLRP3, NMI, NMUR1, NOD2,	
	NPFFR2, OLR1, OPRK1, OSM, OSMR, P2RX4, P2RX7, P2RY2, PCDH7,	
	PDE4B, PDPN, PIK3R5, PLAUR, PROK2, PSEN1, PTAFR, PTGER2,	
	PTGER4, PTGIR, PTPRE, PVR, RAF1, RASGRP1, RELA, RGS1, RGS16,	
	RHOG, RIPK2, RNF144B, ROS1, RTP4, SCARF1, SCN1B, SELE, SELENOS,	
	SELL, SEMA4D, SERPINE1, SGMS2, SLAMF1, SLC11A2, SLC1A2, SLC28A2,	
	SLC31A1, SLC31A2, SLC4A4, SLC7A1, SLC7A2, SPHK1, SRI, STAB1, TACR1,	

	TACR3, TAPBP, TIMP1, TLR1, TLR2, TLR3, TNFAIP6, TNFRSF1B, TNFRSF9, TNFSF10, TNFSF15, TNFSF9, TPRG, VIP	
Cytokine-related genes	<i>IL2, IL7, CSF3, CXCL10, CCL2, CCL3, TNF, TFTN1, IL6</i>	PMID: 32192578
Cytokine-related genes	CXCL10, CCL7, IL1RN, CSF1, IFNG, IL6, IL2RA, IL10, IL18, HGF, CXCL9, CSF3, CCL3, CCL27	Exuberant elevation of IP-10, MCP-3 and IL- 1ra during SARS- CoV-2 2 infection is associated with disease severity and fatal outcome, 2020.3, <i>MedRxiv</i>
Cytokine-related genes	TGFB1	PMID: 32346099
Cytokine-related genes	IL1B, LTA, IFNG, CSF1, CSF2, LTB, IL6, TNFSF13, IL18, IL2, IL4	PMID: 32377375
Cytokine-related genes	IL1B, IL18, IL6, TNF, CCL2, CCL7, CCL12, CXCL8, CCL3, CXCL9, CXCL10, CXCL11	PMID: 32505227
Cytokine-related genes	ILIB, IL6, TNF, CCL2, CCL3, CCL4, CCL7, CXCL9, CXCL10, CXCL11, CXCL1_CXCL2_CXCL3_CXCL8_CCL3L1_CCL8_CXCL16	PMID: 32398875
Cytokine-related genes	IL6, CXCL8	PMID: 32434211
Cytokine-related genes	CSF2, IL6, IFNG	Pathogenic T-cells
		and inflammatory
		monocytes incite
		inflammatory storms
		in severe COVID-19
		patients, 2020.6,
		National Science
		Review
Cytokine-related genes	IL6, IL10, CXCL8, CXCL10, IFNG, IFNA1	A consensus Covid-19
		immune signature
		combines immuno-
		protection with
		discrete sepsis-like
		traits associated with
		poor prognosis.,
		2020.6, medRxiv
Cytokine-related genes	CXCL10, CXCL9, CCL2, IL1RN, CCL5, CCL11, TNF, HGF, IFNA2	PMID: 32669297
Cytokine-related genes	TNF, IL1B, IL18	PMID: 32651212
Cytokine-related genes	TNF, CCL3, CCL4, CCL20, IL1B, IL6, IL10, CXCL2, CXCL3, CXCL8, CXCL9, CCL3L1, CCL4L2	PMID: 32764665
Cytokine-related genes	IL6, CXCL10, CCL7, HGF, OSM, TNFSF14, IFNA1, SA100A12, FGF19, CXCL5, CCL4, CCL8, CCL19, CXCL11, CCL3, IL18R1, CSF1, TNF, CCL20, TGFA, IFNB1	PMID: 32788292

Cytokine-related genes	TNF	PMID: 32877699
Cytokine-related genes	IL6, IL8, TNF, IL1B	PMID: 32839624
Cytokine-related genes	IL17C, TNFSF10, FGF7, XCL1, FGF13, LIF, TGFB3, INHBE, CERS1, TXLNA, IFNW1, IL22, XCL2, CCL25, CCL16, CD40LG, IL20, FASLG, TPO, SCYL3, PF4V1, TNFSF8, GDF15, IL1A, VEGFA, GDF7, BMP6, PDGFA,	KEGG database (PMID: 10592173)
	IL21, ABCD-1, ABCD-2, PDGFB, TNFSF4, FAM19A1, HBEGF, PDGFD, IL12RB2, GH1, VEGFB, MIP3B, IL27, PF4, BMP8B, TNFSF12, IL15, SCYL2,	
	VEGFC, CCL18, TNFSF11, IL12A, EB3, AMH, IL26, IL32, PGFC, FGF23, IGE1 IL1ELL CCL28, CLCEL TNEEFO, PMP3 IL24, CDE10, CYCL6	
	GDF9, IL23A, IL16, CD70, IL5, FGF9, IFNL1, TSC1, FGF2, IL23R, IL1G, SPP1 IL27R1 RMP4 IL13 TPARI TGFP2 FAM1042 AGIF3 FDA MIF	
	TNFSF13B, BMP7, FGF18, CCL23	
Genes in the KEGG	GDF11, CCL26, CXCL13, CXCR6, TNFSF13B, CCR9, CCL27, EDAR, IL24, ILIZE TNERSE13C, CCR1, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CNTF	KEGG database
pathway of cytokine-	CNTFR, ACVRIC, ILI7RE, IL3IRA, CSF1, CSF1R, CSF2, CSF2RB, CSF3, CSF2R, CSL1, CSL1, HARA, CTF1, LS7R, CSF1R, CSF2, CSF2RB, CSF3,	(PMID: 10592173)
cytokine receptor	CSF3R, CSH1, CSH2, 1L34, C1F1, 1L23R, GDF7, CX3CR1, IFNLR1, EDA, EPO, EPOR, TNFRSF13B, CLCF1, IL17RA, IL27, IL36RN, GDF1, GDF2,	
interaction (hsa04060)	MSTN, GDF9, GDF10, AMH, GH1, GH2, AMHR2, GHR, IL36B, IL37, IL36A, IL17C, IL17B, TNFRSF21, BMP10, CCR10, IFNL2, IFNL3, IFNL1, XCR1,	
	CXCR3, CXCL17, CXCL1, CXCL2, CXCL3, IL19, IFNE, IFNA1, IFNA2, IFNA4, IFNA5, IFNA6, IFNA7, IFNA8, IFNA10, IFNA13, IFNA14, IFNA16,	
	IFNA17, IFNA21, IFNAR1, IFNAR2, IFNB1, IFNG, IFNGR1, IFNGR2, IFNW1, BMP8A, FAS, IL1A, IL1B, IL1R1, IL1RAP, IL1RN, IL2, IL2RA,	
	FASLG, IL2RB, IL2RG, IL3, IL4, IL4R, IL5, IL5RA, IL6, IL6R, IL6ST, IL7, IL7R, CXCL8, CXCR1, IL9, CXCR2, IL10, IL10RA, IL10RB, IL11, IL11RA,	
	IL12A, IL12B, IL12RB1, IL12RB2, IL13, IL13RA1, IL13RA2, IL15, IL15RA,	
	CCL4L1, GDF6, LEP, LEPR, LIF, LIFR, LTA, LTB, LTBR, CCL3L3, CXCL9,	
	MPL, NGF, NGFR, NODAL, TNFRSF11B, OSM, IL20, IL21R, IL22, TNFRSF12A, ACKR4, IL23A, PF4, PF4V1, IL17D, IL20RA, IL20RB, PPBP,	
	TNFRSF19, IL17RB, IL26, PRL, PRLR, IL36G, CCL28, IFNK, ACKR3,	
	CCL4, CCL5, CCL7, CCL8, CCL11, CCL13, CCL14, CCL15, CCL16, CCL17,	
	CCL18, CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CXCL6, CXCL11, CXCL5, XCL1, CX3CL1, CXCL12, CXCR5, IL25, BMP2, BMP3,	
	BMP4, BMP5, BMP6, BMP7, BMP8B, BMPR1A, BMPR1B, BMPR2, XCL2, TGFB1, TGFB2, TGFB3, TGFBR1, TGFBR2, THPO, TNF, TNFRSF1A,	
	TNFRSF1B, TNFSF4, CCR2, TNFRSF4, IL1R2, CXCR4, GDF5, INHBE, IL1E10, IL17PC, RELT, TSLP, TNESELL, TNERSE25, TNESEL4, TNESEL3	
	TNFSF12, TNFSF10, TNFSF9, TNFRSF14, TNFRSF6B, TNFRSF18,	
	TNFRSF11A, TNFRSF10D, TNFRSF10C, TNFRSF10B, TNFRSF10A, IL18RAP, IL1RL2, IL18R1, TNFSF18, ACVR1, IL33, ACVR1B, IL1RL1,	
	OSMR, ACVR2A, CD4, BMP15, IL32, ACVR2B, CD27, ACVRL1, TNFRSF8, TNESES, U27PA, CDE15, CVC144, CC1412, CDE3, CD40, CD401G, CD70	
	TNFSF8, 1127KA, GDF15, CXCL14, CCL4L2, GDF5, CD40, CD40LG, CD70, TNFSF15	
Genes in the KEGG	AKT3, RASGRP2, CCL26, VAV3, CXCL13, CXCR6, GNB5, ADCY1, ADCY2,	KEGG database
pathway of chemokine	CCR9, CCL2/, ADCY3, ADCY3, ADCY6, ADCY/, ADCY8, CHUK, ADCY9, CCR1, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, GRK7, CRK, CRKL,	(PMID: 10592173)
signaling pathway	PIK3R6, CX3CR1, ADRBK1, ADRBK2, DOCK2, ADCY4, AKT1, AKT2, PTK2B, FGR, FOXO3, PLCB1, PIK3R5, SHC2, GNA11, GNA12, GNA13,	
(hsa04062)	GNB1, GNB2, GNB3, GNG3, GNG4, GNG5, GNG7, GNG10, GNG11, GNG71, GNG72, GCP10, YCP1, GYCP3, GPK4, GPK5, GPK6, GPR2, GYCP1	
	CXCL2, CXCL3, GSK3A, GSK3B, HCK, HRAS, IKBKB, CXCL8, CXCR1,	
	CXCR2, CXCL10, ITK, JAK2, JAK3, KRAS, RHOA, CCL4L1, SHC4, LYN, ARRB1, ARRB2, CCL3L3, CXCL9, NFKB1, NFKBIA, NFKBIB, NRAS, PAK1,	
	GNG13, PF4, PF4V1, PIK3CA, PIK3CB, PIK3CD, PIK3CG, PIK3R1, PIK3P2, PICR2, PICR3, PICR4, SHC3, GNG2, PPRP, PRKACA, PRKACB	
	PRKACG, PRKCB, PRKCD, PRKCZ, MAPK1, MAPK3, GNG12, MAP2K1,	
	PARD3, CCL28, BAD, PTK2, PREX1, CXCL16, PXN, RAC1, RAC2, RAF1, RAP1A, RAP1B, GNB4, RELA, ROCK1, CCL1, CCL2, CCL3, CCL3L1. CCL4.	
	CCL5, CCL7, CCL8, CCL11, CCL13, CCL14, CCL15, CCL16, CCL17,	
	CXCL11, CXCL5, XCL1, CX3CL1, CXCL12, CXL23, CXL24, CXL25, CXCL6, CXCL11, CXCL5, XCL1, CX3CL1, CXCL12, CXCR5, SHC1, NCF1, S0S1,	
	SOS2, SRC, BRAF, STAT1, STAT2, STAT3, STAT5B, XCL2, TIAM1, CCR2, VAV1, VAV2, WAS, CXCR4, PIK3R3, IKBKG, WASL, GNG8, ROCK2.	
	CXCL14, CCL4L2, BCAR1, ELMO1, CDC42	

431

432 Supplemental Table S11. Highly-expressed inflammatory and cytokine genes among *CCR1*+ 433 CD16+monocytes

Gene	T score	Fold change	P value	FDR
ADM	6.26	1.72	5.17E-10	2.97E-08
AHR	5.16	1.71	2.83E-07	1.07E-05
AQP9	5.70	1.96	1.47E-08	7.07E-07
C3AR1	6.30	1.56	3.99E-10	2.31E-08
CCL3	6.16	1.55	9.43E-10	5.26E-08
CCL3L1	5.57	1.71	3.01E-08	1.37E-06
CCL4L2	3.06	1.92	2.28E-03	2.49E-02
CD14	18.55	2.14	2.02E-68	1.57E-64
CD82	3.98	1.59	7.16E-05	1.43E-03
CSF3R	7.18	1.56	1.16E-12	9.94E-11
CXCL10	4.17	3.36	3.29E-05	7.14E-04
CXCL2	7.12	2.72	1.83E-12	1.53E-10
CXCL3	3.33	3.33	9.03E-04	1.19E-02
CXCL8	5.56	1.52	3.29E-08	1.48E-06
EIF2AK2	7.87	1.95	7.19E-15	7.88E-13
EREG	6.05	2.02	1.92E-09	1.02E-07
FFAR2	5.56	1.92	3.29E-08	1.48E-06
FPR1	10.14	1.53	2.60E-23	5.69E-21
GPR183	2.99	1.69	2.85E-03	2.99E-02
HBEGF	4.55	1.70	5.84E-06	1.57E-04
IL1B	6.66	1.58	3.89E-11	2.65E-09
IL1RN	8.87	2.68	2.54E-18	3.63E-16
IL27	2.90	2.73	3.75E-03	3.67E-02
IL4R	3.29	1.58	1.04E-03	1.33E-02
ITGA5	2.85	1.53	4.39E-03	4.17E-02
LDLR	4.06	1.72	5.11E-05	1.05E-03
MARCO	7.60	1.66	5.50E-14	5.44E-12

МҮС	3.12	1.90	1.83E-03	2.11E-02
NLRP3	4.92	1.61	9.51E-07	3.16E-05
OSM	2.92	1.82	3.53E-03	3.51E-02
PTAFR	6.99	1.85	4.44E-12	3.42E-10
RTP4	3.35	1.80	8.32E-04	1.11E-02
SELL	9.16	1.94	1.92E-19	3.18E-17
SPHK1	4.81	2.25	1.71E-06	5.32E-05
STAB1	7.78	2.40	1.56E-14	1.65E-12
TNFAIP6	3.44	3.33	5.94E-04	8.43E-03
CCL2	3.36	5.74	8.08E-04	1.08E-02

436

Supplemental Table S12. Pathway enrichment analysis of 351 highly-expressed genes among *CCR1*+ CD16+monocytes.

Pathway name	Gene size	Enrichment	P Value	FDR
		ratio		
NOD-like receptor signaling	168	4.25	4.32E-07	9.07E-05
pathway				
Influenza A	171	4.17	5.56E-07	9.07E-05
Cytokine-cytokine receptor	294	3.14	1.61E-06	1.75E-04
interaction				
Hematopoietic cell lineage	97	5.19	2.83E-06	2.31E-04
Pertussis	76	5.52	1.12E-05	7.32E-04
Salmonella infection	86	4.88	3.39E-05	1.84E-03
Legionellosis	55	6.10	4.16E-05	1.94E-03
Staphylococcus aureus infection	56	5.99	4.75E-05	1.94E-03
Complement and coagulation	79	4.78	9.93E-05	3.60E-03
cascades				
Toll-like receptor signaling	104	4.03	1.73E-04	5.63E-03
pathway				
TNF signaling pathway	110	3.81	2.74E-04	8.13E-03
NF-kappa B signaling pathway	95	3.98	4.09E-04	1.11E-02

Malaria	49	5.14	1.01E-03	2.52E-02
Hepatitis C	131	3.20	1.10E-03	2.56E-02
Herpes simplex infection	185	2.72	1.50E-03	3.26E-02
Chemokine signaling pathway	189	2.66	1.80E-03	3.67E-02
Amoebiasis	96	3.50	1.98E-03	3.79E-02
Human cytomegalovirus infection	225	2.42	2.71E-03	4.91E-02
Chagas disease (American	102	3.29	2.90E-03	4.97E-02
trypanosomiasis)				
Phagosome	152	2.76	3.32E-03	5.42E-02
Cytosolic DNA-sensing pathway	63	4.00	3.71E-03	5.77E-02
Measles	132	2.86	4.16E-03	6.17E-02
Transcriptional misregulation in	186	2.48	4.78E-03	6.77E-02
cancer				
IL-17 signaling pathway	93	3.16	6.57E-03	8.92E-02
Glycosaminoglycan degradation	19	6.63	9.74E-03	1.27E-01
JAK-STAT signaling pathway	162	2.33	1.51E-02	1.90E-01
Bladder cancer	41	4.09	1.59E-02	1.92E-01
Acute myeloid leukemia	66	3.18	2.01E-02	2.19E-01
Inflammatory bowel disease (IBD)	65	3.23	1.90E-02	2.19E-01
Rheumatoid arthritis	90	2.80	2.01E-02	2.19E-01
RIG-I-like receptor signaling	70	3.00	2.53E-02	2.66E-01
pathway				
Tuberculosis	179	2.11	2.70E-02	2.75E-01
Nicotinate and nicotinamide	30	4.20	3.37E-02	2.97E-01
metabolism				
PPAR signaling pathway	74	2.84	3.12E-02	2.97E-01
Osteoclast differentiation	128	2.29	3.29E-02	2.97E-01
Leishmaniasis	74	2.84	3.12E-02	2.97E-01
Kaposi sarcoma-associated	186	2.03	3.34E-02	2.97E-01
herpesvirus infection				

Antifolate resistance	31	4.06	3.67E-02	3.15E-01
Th17 cell differentiation	107	2.35	4.22E-02	3.52E-01
Glycosphingolipid biosynthesis	15	5.59	4.84E-02	3.85E-01

Supplemental Table S13. Druggble proteins collected from the ChEMBL database

Categories	Protein lists	Resources
1,263 human druggable	HGNC_SYMBOL, HTR3E, PSMD12, PLK4, PIK3R2, PSMD14, MSTN, PSMA7_XPO1_DCLK1_PLA2G10_PDPK1_CYP26A1_MINR_MGAM	PMID: 33837377
proteins	HCRTR2 CACNAIF RRDA NR112 GMNN STK16 TRPA1 DGAT1 PAK3	
I	HTR3R BMP10 ABCA1 ARHD16A E8 F9 TNF IENA1 IENG IGHE EN1	
	TTR CXCL10 CSF2 MAS1 CD74 CD3D SHBG TRAV29DV5 IGF1	
	CYP17A1, IL5, SERPINE1, CYP1A2, IL6, LCK, CDK1, CD2, CEACAM5.	
	CALCA. LIPF. TUBB. CHRM4. SERPINA6. MMP2. PTPRC. MYL3. HCK.	
	CYP3A4, CYP21A2, HTR1A, CD3G, ALOX5, WEE2, CD28, RARB, THRA,	
	MYL2, HSPA8, CHRM1, PIM1, TOP1, TOP2A, DMD, CDK4, IMPDH2,	
	FCGR1A, SRC, MYH6, RARG, ADRB3, FOLR2, SI, INSRR, PKM, TYR,	
	GABRA1, IFNGR1, FOLR1, CD19, ELN, CYP11B1, PNLIP, ENG, FLT1,	
	ADRA2B, GABRB1, GABRG2, CYP11B2, RXRA, ERBB3, GART, CDH3, CA4,	
	MMP8, PPIB, EDNRB, HRH2, BRD2, PSMA1, PSMA3, HSD3B2, CD27,	
	PIK3R1, PSMB8, PSMB9, PSMB4, PSMB6, RXRB, HSD11B1, CTGF,	
	CD40LG, AVPR2, CALCR, SRD5A2, SSTR3, CNR2, TRHR, PTGS2, OPRM1,	
	SCN4A, PDE6B, IFNGR2, THPO, MPL, ADH7, CASR, GRM5, MC3R,	
	AKR1C3, PIK3CA, CA7, NR4A2, KIR2DL1, KIR2DL2, KIR2DL3, PSMC4,	
	TNNT2, MMP13, NOTCH1, AVPR1B, MTNR1A, CSNK1A1, PIK3CG,	
	MAPKAPK2, PSMB3, CLK1, CLK2, GSK3A, AGTR2, CDK7, IRAK1, PSMD7,	
	CCR4, CCR9, BMX, KIF11, EPHB3, LOXL3, PSMC1, RBX1, TNNC1,	
	TUBA4A, TUBB4B, HBB, HBA1, HBA2, PIP4K2B, HAMP, MUCSAC, CDK6,	
	CDK5, CDK1/, NFKB2, SCN/A, FKBP4, KM12A, RELA, NOICH2, ACVR1,	
	GKINI, BIK, LIB, PDE4B, PDE4D, MAP4K2, SLCIUA2, GKIN2B, PDE3B, EKRD5, DDDE4D, HTD4, NCO44, IKDKE, H 12DA2, MELK, ND112, EDD	
	FRBF3, PRFF4B, H1R4, NCOA4, IRBRE, ILISKA2, MELR, NRIIS, EBP,	
	SHH, MILK, KUNJO, ADKMI, NFEZLZ, KFEOJ, DDBI, BULZAI, ILI/A, CVP2413 AOC3 MGAM2 HLA DRR1 MVLK3 SLC2246 SLC4444	
	TMFM97 TURA1A MARK2 SV2A KCNK18 TPH2 PSMA8 SLC22A8	
	MAPK15 HDAC2 BCL2L2-PABPN1 GHSR MAP4K1 APH1A AURKB	
	SLC46A1. PVRI4. TAAR1. HBEGF. HSD17B10. TSSK1B. HDAC8. FGF23.	
	IL22. HIPK3. CYP3A43. CD248. PDE7B. TNFRSF12A. KCNK9. DLL4.	
	PSENEN, PIM2, HDAC6, GABBR1, GDF2, CA14, NOTCH3, GABRO, SRPK3,	
	AKT3, HCN4, ANGPTL3, HRH3, SCN10A, ICOS, TNFSF11, TNFSF14, LTA,	
	CD4, MMP3, IL8, PDGFRA, TNFRSF9, DDR1, GLA, NCAM1, HGF, IL6ST,	
	AKR1C1, MPO, IL12B, IL5RA, PSMB11, MYH7B, PSMD11, BMPR1B, CDC7,	
	PIK3CD, STK25, FAAH, CACNA1A, GABRP, KCNK3, RIOK3, TERT, CHEK1,	
	GABRD, FFAR1, IKBKB, AURKA, GAK, NPC1, ANGPT2, HDAC3, GRIN2D,	
	TLR3, KCNN4, PRPF4, GPR39, PSMD3, MAP3K13, DAPK3, MAP3K7,	
	RIPK2, CACNA1G, KCNQ3, KCNQ2, CA12, HCRTR1, PSCA, PDE6D,	
	AKR1B10, NUAK1, GRIN3B, CCNT1, PDE8A, JAK2, ABCC9, RAMP1, CTSV,	
	FZD7, ROCK2, GUCY1B2, NCOR1, ULK1, CA11, RPS6KA5, RPS6KA4,	
	IDH1, TNFSF13, GABBR2, PDE5A, STK10, PRKD3, KCNK2, S1PR2,	
	CACNAIH, PDE8B, TNKS, ESRRB, MAP4K4, GLP2R, SIPR4, PAK4, CHEK2,	
	ADHIB, ADHIC, ALDHIAI, DHFR, GSR, PAH, SODI, PNP, ABLI, CFD,	
	F12, PLAI, CAI, CA2, SERPINCI, C5, PDGFB, NGF, IGF2, ILIA, ILIB,	
	IKAC, LMINA, INNCZ, FGB, CHRNAI, AFP, GC, ESKI, KLKBI, IKGVS,	
	NITERI TESS AMVOA CVELAL TVMS ATELAL ATELEL ADE ALDES	
	ITGR3 ITGR2 CYP11A1 IIA PRKCG FGF1 ITGR1 PRKCR INSR FYN	
	BCHE, PGR, EIF4E, NPM1, ITGAV, TH TPO, KLK3, H1F0, ADH1A, FFS	
	CSF1R, CHRNG, ADRB2, CD3E, HSP90AA1, YES1, LYN, IGF1R, CHRM2	
	ABCB1, NR3C2, HSP90AB1, ADH4, MME. INHBA. ITGA2B. MET. ADRB1.	
	FCGR3A, ITGA5, VIM, STS, CHRM5, ADRA2A. ROS1. FGF2. HMGB1.	
	TACSTD2, FGR, PARP1, LTA4H, ADORA3, CALM1, TUBA3C, CALCB, GAA.	
	AR, RARA, ARAF, BCL2, TGFB3, CYP2D6, MAPT, KIT, THRB, CD37, UMPS,	
	ITGAM, CHRNB1, BCR, FGFR1, VDR, ESRRA, CYP2A6, CYP19A1, CETP,	
	CYP2C9, ADH5, MS4A1, ODC1, ACE, MYL4, MYH7, CCL2, CFTR, ITGA4,	

ATP1A3, EEF2, SLC5A1, HSD17B1, FDPS, DRD2, IL2RB, BRAF, GLUL, IL9,	
CSF2RA_PHKG2_MUC1_ALOX15_NPR1_CD44_CTLA4_EPCAM_DPEP1	
TSUD DDECA SELE EED DDECA JECA DDEACA TVDD1 TDU1	
ISHK, PDEOA, SELE, FEK, FKKCA, IIGA2, FKKACA, IIKF1, IFH1,	
CHRNB2, CR1, PSMC3, ALOX12, ITGB5, SRD5A1, PDE6G, ITGB6,	
ADRA2C, SDC1, EPOR, TNNI3, AOC1, NFKB1, TYMP, CD22, ALOX5AP,	
CHRM3, PSMB1, ATP4A, ITGAL, DDC, CYP3A5, IMPDH1, MAG, MAOA,	
TACR2 SIPRI CNRI DRDI C5ARI TBXA2R EGER2 RYRI DRD4	
DDD5 COMT II 10 ACHE ECEDA ECED2 DDVACC DDVACD LUCCD	
DKD3, COM1, IL10, ACHE, FGFR4, FGFR5, FKRACG, FKRACB, LHCGR,	
PTGS1, GLRA1, RPS6KB1, JAK1, TNFSF4, CPT2, RRM1, FSHR, CMA1,	
SLC6A2, GABRR1, CCND1, CYP3A7, TBXAS1, PRKCH, CCNE1, CDK2,	
CXCR1, CXCR2, GUCY2C, ADRA1D, EDNRA, TACR1, PTAFR, PSMA2,	
PSMA4 ITGR7 DNMT1 II 3RA MAOR MAPK3 MARK3 DPP4 PDF4A	
DCMA5 DCMD5 UTD1D UTD1D UTD1A ADUK UTD1C CADDD2 MADK1	
PSMAJ, PSMBJ, HIKID, HIKIB, HIK2A, ADHO, HIK2C, GABKBJ, MAPKI,	
TNFRSF8, IMPA1, ADORA2A, ADORA2B, EPHA2, EPHA3, EPHA8, TACR3,	
LTK, CASP1, TYK2, CD6, CCND2, CCND3, WEE1, BDKRB2, SLC6A1,	
CHRNA5, TSPO, ADORA1, AGTR1, OXTR, SSTR1, SSTR2, CHRNB4, HTR1F,	
CNDHD NTSD1 CDS1 DDM2 CD52 SSTD4 SLC542 CADD45 SLC644	
GINRIR, MISKI, CFSI, RRM2, CDS2, SSIR4, SECJA2, GABRAJ, SECOA4,	
AKT1, AKT2, ATIC, CCKAR, CCKBR, MC4R, CCR1, CHRNA3, GRK4, HPD,	
ICAM3, CD70, MC5R, KIF5B, CYP2C19, GUCY1A2, ABCC1, CD80, TTK,	
GABRA3, EPHX2, HTR7, PTGER1, CRHR1, IL13, SSTR5, ADRA1A, HRH1,	
ADRAIR PTGERA DRD3 SCN1A SOATI RSG CHKA PSMC2 MAP2K2	
CUDNAZ ELT2 TOEDD1 CONNIA DDADO EDET1 AVDD1A COON	
CHRNA/, FLI3, IGFBRI, SCNNIA, PPARG, FDFII, AVPRIA, GGCX,	
GRIK1, PLA2G5, CD79B, PSMB10, IL15, PMEL, OPRD1, OPRK1, OPRL1,	
P2RY2, HNF4A, CSK, IARS, SLC19A1, HTR2B, CCR2, PRKCI, CD86, GRIA1,	
GRIA2, GRIA3, PIK3CB, MTOR. TEC. TXK. ABL2 FRK HTT PTGFR	
PTGERS PTGERS PTGIR MCAM CIDID CTCK CODD CVK TNEDCEA	
LIGERS, LIGERZ, LIGIR, WORW, OLFIR, CISK, GFDZ, SIK, INFKSF4,	
NAMPT, CHRNA4, TNNT3, MAPK8, MAPK9, RECQL, HTR3A, BDKRB1,	
GABRA2, GABRB2, GCGR, SCTR, HTR5A, XDH, GRIA4, SLC6A9, GABRA4,	
RXRG, IFNAR2, PSMD8, CSNK1D, IDH2, SLC9A3, TNNI2, MTNR1B, CDK8,	
ENTA ENTR CSNKIE PSMR2 PGE VEGER PSENI PSEN2 GSK3R	
DIGI NEVAD UTEC CENCO ATELIAA BARGA DEECC ATEAD CONNUD	
DIO1, NPY4R, HIRO, CDK9, AIPIA2, RAB9A, PDE6C, AIP4B, SCNNIB,	
SCNN1G, RORC, BLK, CYP2J2, ALDH5A1, CCL11, CCR5, KCNQ1, CLCN2,	
RPS6KA3, JAK3, PLK1, DAPK1, COL4A4, LIMK2, MAPK12, MAPK10, BLM,	
CACNA2D1 PRKAA2 ATP1B3 FXYD2 EPHA5 EPHB1 EPHA4 SLC12A3	
DSMD4 ND1H2 MTTD CASDO CEED D2DV2 HDAC4 VCNO4 DACE1	
PSMD4, NRIH2, MIIP, CASP9, GFER, P2RXS, HDAC4, KCNQ4, BACEI,	
CLDN18, SIK1, KCNK10, SHFM1, PSMA6, CXCR4, TGFB2, PSMC5, PSMC6,	
ESRRG, PPIA, FKBP1A, KCNJ2, FKBP1B, TUBA1B, CSNK2A1, GABRE,	
SRPK2, PRKDC, ADAM17, IL13RA1, MAP3K9, HSD11B2, ABAT, CDK16,	
CACNAIR MDM2 MVI7 PMP22 MVT1 CACNAID MC2R MC1R	
CACNAID, MDM2, MIL/, I MI 22, MIII, CACNAID, MC2K, MCIK,	
SLC6A3, GUCYIA3, DHODH, GUCYIB3, PRKCE, RHD, GHRHR, MAP2KI,	
MAP3K10, TOP2B, PPARD, PTH1R, FOLH1, PRKCQ, CHRNE, MST1R,	
PTK2, PRKCZ, PRKCD, CHRNB3, SLC18A2, PPAT, AOX1, TYRO3, CHRND,	
RCL2L1 MCL1 PPARA TNK2 CYP24A1 PPP3CA PDF4C PPID ITK	
DMBK ABCC9 KCNMA1 KCNU2 MAD2K12 CDIN2A DDVD FAD	
DMPK, ABCCO, KCNMAI, KCNH2, MAP5K12, GKIN2A, DP1D, FAP,	
GRIK2, GRIK3, STK4, PLA2G7, PRKAA1, NR1H3, MAP2K5, PAK2, STK3,	
PSMD2, MAP3K1, PRKG2, PTGDR, GPR17, MSLN, IKZF1, ROCK1, FZD5,	
TNK1, MADCAM1, BIRC3, BIRC2, TUBB3. ATR. HDAC1. CAMK2G.	
CAMK2D NAFI CULAA SICI2AL DVRKIA TORC CACNAIS ACVO2D	
ATDIAA DMDDO DTVG TUDDOA CACNAIC DDETA DDECH DDVCI	
ATT TAT, DIVIENZ, ETNO, TUDDZA, CACIVATC, FDE/A, FDEOR, FKKGI,	
IL18, KEAP1, PTK2B, FZD2, GRM2, PDE3A, SCN5A, SQLE, KCNJ11, GRM3,	
GRIN2C, PSMD6, BRD3, PDCD1, PDK1, PDK2, PDK3, PRKD1, ERBB4,	
RPS6KA2, DHCR24, SF3B3, RYR3, RPS6KA1, TESK1, LTB4R, MAPK11,	
NPY5R CHRNA2 CHRNA6 STK11 GRK1 SCN9A GRIK4 CCDC6	
CADDAG CRIKE REAL REAL MADELA MADELL CALCRE NTRE	
GABRAO, GRIKS, PKNI, PKN2, MAPK14, MAP3K11, CALCKL, NIKK2,	
SMN2, PDK4, HIF1A, UGCG, CA9, PHKG1, DDR2, CYP51A1, TXNRD1,	
AAK1, TUBB8, PDCD4, MAP3K19, BRDT, TNNI3K, LRRK2, ANO1, CD276,	
TUBA3E, ULK3, NPSR1, HTR3D, TRPM8, DPP9, PIM3, MYLK4, HIPK1,	
IFNIRI CAMKID MAPAK3 MAPKAPK5 IIIKO CARRCI CAIZ ADUDIO	
MINEL DACID HIDEA TODUL TODUL LIDAL CODIAL CTURE HICES	
MIINKI, DAGLB, HIPK4, IKPVI, IKPV3, UBA3, GRIN3A, STK35, HCAR2,	
GPBAR1, GRK7, CLEC4C, HDAC7, APH1B, HTR3C, RXFP2, MUC16,	
PIK3R5, CPT1B, NCSTN, PIK3R3, ESR2, RORB, BCL2L2, SLCO2A1, BHMT,	
TSLP. TOP1MT. HDAC10. HDAC11. LINGO1_SLC47A1_LOX14_FGLN2	
ND1HA CAMERY SICONAL CODVI CODVI CODVI CODVI CONVA DOMDZ	
INTITY, CANINAL, SLUZZATZ, SKENT, UKDIN, USESK, SUNZA, PSMB/,	
PSMD1, SIPR3, GPER, P2RX7, PKMYT1, MAP3K5, SIGMAR1, PIP5K1A,	
MAP3K3, GPA33, SLC29A1, EPAS1, TSG101, SMO, GABRG3, SOST,	
VKORC1, TUBA1C, RIOK1, TUBB6, ABHD6. TUBB2B. RIOK2. EBPL. ACE2.	
STK33 DCLK3 FGLN1 CHRNA10 NIIAK2 PARP12 SIK2 MVLK2 SIDD5	
DODVIO CLA TAMAO TAMA DIMATO HUDRO HUDRO COMO EZDO TUDO	
F2K112, SLK, INKS2, IAOK3, BHM12, HIPK2, HRH4, SRMS, FZD8, TUBBI,	
EGLN3, SRD5A3, CLK4, TRPV4, RXFP1, NOD2, EML4, GPR35, PDE11A,	

	BCL2L10, IL23A, RTN4, KCNQ5, TLR9, CYSLTR2, SLC22A11, BMP2K.	
	TDP1, IRAK4, SIRT5, P4HTM, SCN3A, CACNA2D2, SLC5A4, TLR7,	
	MAP3K20, IL20, CISD1, CACNA11, STK26, RCOR3, EIF2AK4, DHCR7,	
	RPS6KB2, MALT1, STK17A, EPHA6, CHRNA9, PARP2, NPC1L1, TBK1,	
	STEAP1, EGFL7, SCN11A, DAPK2, TNIK, UTS2R, IKZF3, HDAC9, ALK,	
	CELA1, PSMD13, FZD1, TFR2, AURKC, SCN8A, HDAC5, CAMK2A,	
	PDE10A, HPSE, CYSLTR1, CA5B, NISCH, SIK3, MAP3K2, DYRK1B,	
	L3MBTL1, DAGLA, LOXL2, MAP4K5, TNFRSF18, PTGDR2, IRAK3, NCOR2,	
	STK24, PARP3, DNMT3A, MAP3K4, TNFRSF10A, TNFRSF10B, EGFR, REN,	
	ADA, TGFB1, IL2RA, TFRC, MMP1, CD5, MMP7, CSF1, SPP1, IL1R1,	
	TNFRSF1A, IL4R, F2R, CD40, CD38, AXL, CA5A, LTBR, ACVRL1, CD200,	
	SULT1A1, EPHB4, IL10RB, MERTK, CASP8, ANGPT1, NTRK3, PCSK9,	
	CD274, TNFSF13B, F2, PLG, CD14, TLR4, NRP1, MAPK13, ICOSLG, DKK1,	
	ICAM1, FCER2, CA3, RET, GSTP1, PDGFRB, GHR, PTHLH, TDGF1, SELL,	
	ATP1B2, PLA2G2A, MMP9, IDO1, AKR1B1, NQO1, NQO2, CBR1, IFNAR1,	
	CD33, EPHA1, CA6, TNC, EPHB2, CSF2RB, TIE1, FLT4, KDR, SNCA,	
	PTGDS, PRCP, LEPR, VEGFC, IL11RA, GPNMB, RRM2B, LY96, EPHB6,	
	TNFSF12, VEGFA, SELP, MMP12, GFRA1, DLK1, TEK, PDCD1LG2,	
	SLAMF7, F10, MFGE8, IL6R, IL17RA,	
703 human druggable	SIGMAR1, DNMT1, SIRT5, BRD4, BRD2, IL17RA, TLR9, TLR7, ESR1, ESR2,	PMID: 33837377
proteins have avidence for	CSNK2A1, RET, FLT3, PIK3CD, TOP2A, PIK3R1, AXL, PIK3CB, PIK3CG,	
proteins have evidence for	EBP, ALK, PIK3R2, CCNT1, CDK1, ROS1, CDK4, CCND1, CCNE1, CDK2,	
involvement in COVID-	CCND3, PIK3CA, CDK9, CDK6, CDK5, DHCR24, MAPK14, PIK3R5,	
	PIK3R3, ABL1, LMNA, LYN, CHRM4, CHRM5, ADRA2A, PDGFRB, KIT,	
19	BCR, FGFR1, DRD2, PDGFRA, FLT1, ADRA2C, CHRM3, IMPDH1, FGFR2,	
	FGFR4, FGFR3, ADRAID, HTR2A, HTR2C, HRH1, DRD3, KDR, HTR2B,	
	ABL2, HTR6, SMN1, SMN2, PLK4, GAK, NPC1, JAK2, CACNAIF, ROCK2,	
	EGFR, F10, CA1, CA2, NR3C1, ERBB2, TP53, INSR, LCK, FYN, PGR, EIF4E,	
	CSFTR, YESI, IGFTR, ABCBI, HCK, CYP3A4, FGR, KARA, KARB, CHRMI,	
	VDR, CYP2C9, RARG, NQO2, ADRA2B, ATP4A, DRD1, DRD4, PPIB,	
	SLC0A2, AGIKI, SLC0A4, CIP2CI9, HIK7, PIGS2, OPKMI, FL14, IHPO,	
	CSK, MIOK, IEC, IAK, PIGIK, KABYA, BLK, BMA, JAKS, BLM, ESKKO,	
	PPIA, FKBPIA, FKBPIB, CACNAID, FKBP4, UKINI, BIK, PPF5CA, DDKI,	
	CAMEYO CACNAIS DEEG CACNAIC EDEDA CAO DDD2 AAEL DDCDA	
	MAD3K10 SI CA7A1 SPDK1 ERDI NUAK2 CI KA TDD1 DHCP7 SPDK3	
	CAMEYA DIDEY IMDDEY SDC DMDDID AUDEA EDHDG MADEI3	
	PRDEA NIIAKI PAKA AIDHIAI RAFI ATDIAI ATDIRI CVDI7AI	
	PRKCR CHRM2 MET ARAF CYP2D6 THRR PIM1 CVP10A1 CETR	
	ATP1A3 ATP1R2 RRAF CYP11R2 FPHA1 FRRR3 DRD5 CPT2 MAPK3	
	MARK3 MAPK1 FPHA2 FPHA3 FPHA8 FPHR2 CCND2 AKT1 AKT2	
	EPHX2 PTGER1 SCN1A SCN4A TIE1 MPL GRIA1 GRIA2 GRIA3 FRK	
	PTGER2 SYK MAPK8 MAPK9 GRIA4 MAPKAPK2 CDK8 FNTA FNTB	
	CDK7 ATP1A2 PLK1 LIMK2 MAPK12 MAPK10 ATP1B3 FXYD2	
	EPHB3 EPHA5 EPHB4 EPHB1 EPHA4 SIK1 KCN12 MAP3K9 SCN7A	
	MYT1, TEK, ACVR1, TNK2, CYP24A1. PRKG2. TNK1. NAE1. DYRK1A	
	ATP1A4, SCN5A, TESK1, MAPK11, GRK1. SCN9A. PKN1. PKN2. MAP3K11.	
	CYP51A1, TNNI3K, MARK2, PIM3, HIPK4, UBA3. MAPK15. GRK7. CPT1B.	
	AURKB, CAMKK2, SCN2A, PKMYT1, RIOK2, TSSK1B, SIK2, SRMS, EML4.	
	SCN3A, MAP3K20, PIM2, EIF2AK4, TBK1, SCN11A, SCN8A, PDE10A. AKT3.	
	SIK3, HCN4, DYRK1B, MAP4K5, SCN10A, RBX1, IKZF1, CUL4A, DDB1,	
	CRBN, IKZF3, KCNK3, RIOK3, XPO1, DCLK1, GRIN2D, TLR3, DAPK3,	
	MAP3K7, CA12, PDE6D, GRIN3B, GUCY1B2, GMNN, STK16, PDE5A,	
	STK10, KCNK2, S1PR2, ESRRB, S1PR4, DHFR, F2, PLG, REN, SERPINC1,	
	C5, TNF, IFNG, IL1B, KLKB1, MMP1, HMGCR, CSF2, MAS1, SHBG,	
	TUBB4A, NTRK1, TYMS, ITGB3, CYP1A2, IL6, TUBB, ADRB2, SERPINA6,	
	NR3C2, ITGA2B, CD14, ADRB1, IL6R, MMP7, HMGB1, LTA4H, ADORA3,	
	TUBA3C, CXCL8, AR, ESRRA, ACE, SLC5A1, ADRB3, INSRR, IL1R1,	
	CSF2RA, VEGFA, ALOX15, SELP, TSHR, PDE6A, FER, IFNAR1, SRD5A1,	
	PDE6G, NFKB1, CYP3A5, S1PR1, CNR1, GART, ACHE, MMP8, PTGS1, CA6,	
	GLRA1, JAK1, CYP3A7, EDNRB, TBXAS1, HRH2, EDNRA, TACR1, DPP4,	
	HTR1D, ADORA2A, ADORA2B, CCN2, TYK2, CD6, AVPR2, OXTR, GNRHR,	
	SRD5A2, SLC5A2, ATIC, GRK4, CSF2RB, CD80, TTK, ADRA1A, ADRA1B,	
	PDE6B, MAP2K2, AVPR1A, OPRD1, OPRK1, SLC19A1, CD86, AKR1C3,	
	CA7, MMP13, AVPR1B, MTNR1A, IFNAR2, MTNR1B, CLK1, GSK3B, AGTR2,	
	PDE6C, CYP2J2, CCR5, RPS6KA3, DAPK1, PRKAA2, KCNK10, TUBA1B,	
	TUBA4A, TUBB4B, PIP4K2B, SRPK2, CDK16, CDK17, SLC6A3, DHODH,	
	GUCY1B1, MAP2K1, TOP2B, AOX1, IL10RB, ITK, MERTK, GRIN2A, FAP,	
	PRKAA1, TUBB3, CAMK2G, BMPR2, TUBB2A, PDE6H, PRKG1, PTK2B,	

MELK, GRIN2C, PDCD1, RPS6KA2, SF3B3, STK11, NTRK3, IL17A, NTRK2,	
HIF1A, TUBB8, LRRK2, TUBA3E, AC091230.1, NPSR1, TUBA1A, KCNK18,	
IFNLR1, MINK1, GRIN3A, MAP4K1, S1PR3, GPER1, HSD17B10, PIP5K1A,	
MAP3K3, SLC29A1, TUBA1C, RIOK1, TUBB6, TUBB2B, DCLK3, S1PR5,	
P2RY12, SLK, TUBB1, SRD5A3, CYP3A43, KCNK9, CYSLTR2, BMP2K,	
SLC5A4, STK26, DAPK2, TNIK, CYSLTR1, MAP3K2, PTGDR2, GLA, COMT,	
BRD3, F8, IL2RA, FGB, VWF, CD2, CD3E, ALOX5, MS4A1, ITGA4, PKM,	
IL2RB, GLUL, IFNGR1, NQO1, ALOX12, ITGAL, CXCR1, CXCR2, F2R,	
ITGB7, HSD3B2, PDE4A, IL12B, CD52, PPARG, IFNGR2, CCR2, RECQL,	
CXCR4, ADAM17, PPAT, PDE4B, PDE4C, AC008397.2, PDE4D, PTGDR,	
GPR17, KEAP1, PDE3A, IL11RA, TXNRD1, CA13, CSF3R, VKORC1, HRH4,	
NOD2, GPR35, IL23A, TNFSF13B, CA5B, HRH3, ACE2, TLR4, PSMD11,	
CDC7, PSMD14, STK25, TNFRSF10B, PSMA7, PDE8A, CTSV, NCOR1,	
ULK1, IDH1, TNFSF13, CHEK2, PLAT, ADA, IL1A, TTR, AFP, CXCL10,	
TFRC, APOB, TK1, CD74, APP, ALDH2, IL4, MPO, ITGB1, CEACAM5,	
NPM1, ITGAV, H1-0, HSP90AA1, HSP90AB1, ITGA5, VIM, GSTP1, CSF1,	
PARP1, CALM1, BCL2, SPP1, HSPA8, TOP1, ADH5, CCL2, EEF2, PLA2G2A,	
AKR1B1, FOLR1, CD19, PHKG2, MUC1, CD44, EPCAM, PRKCA, PRKACA,	
TNNI3, DDC, IL10, PRKACG, PRKACB, RPS6KB1, RRM1, PSMA2, PSMA3,	
PSMA4, PSMB9, PSMA5, PSMB5, BDKRB2, CPS1, RRM2, KIF5B, GUCY1A2,	
ABCC1, SOAT1, BSG, PSMC2, SNCA, GGCX, IL6ST, HTT, GLP1R, GPD2,	
PSMC4, BDKRB1, PSMD8, IDH2, PSMB3, PSEN1, GSK3A, PSMD7, KIF11,	
NR1H2, GFER, HDAC4, PSMA6, PSMC1, PSMC5, HBA2, HBA1, PRKDC,	
NFKB2, KMT2A, PTK2, PRKCZ, PRKCD, BCL2L1, MCL1, MFGE8, PAK2,	
PSMD2, MAP3K1, HDAC1, IL18, PSMD6, PDK1, RPS6KA1, SHH, MYLK,	
ADRM1, CCDC6, BCL2A1, TMEM97, RRM2B, DPP9, MAPKAPK5, ABHD12,	
PCSK9, TRPV1, HDAC7, MUC16, HDAC2, BCL2L2, BCL2L2-PABPN1,	
PSMD1, GPA33, TSG101, IL22, RTN4, RPS6KB2, STK17A, PSMD13, NCOR2,	
STK24	

440 Supplemental Table S14. Functional enrichment analysis of 190 up-DEGs associated with 441 severe COVID-19 based on the Reactome database

Description	Size	Ratio	P Value	FDR
Immune System	1997	2.56	1.65E-14	2.86E-11
Innate Immune System	1053	3.24	1.79E-12	1.55E-09
Neutrophil degranulation	479	4.07	3.39E-09	1.95E-06
Negative regulators of DDX58/IFIH1 signaling	34	16.71	1.49E-07	6.45E-05
Cellular responses to external stimuli	503	3.23	3.15E-06	1.09E-03
DDX58/IFIH1-mediated induction of interferon-	78	8.33	4.86E-06	1.40E-03
alpha/beta				
Interleukin-4 and Interleukin-13 signaling	108	6.77	6.92E-06	1.71E-03
Adaptive Immune System	756	2.58	1.45E-05	3.13E-03
Interferon alpha/beta signaling	69	8.24	2.09E-05	4.02E-03
Cellular responses to stress	426	3.05	6.63E-05	1.15E-02
Regulation of TLR by endogenous ligand	19	17.09	7.38E-05	1.16E-02
Cytokine Signaling in Immune system	688	2.48	9.46E-05	1.36E-02
Interferon gamma signaling	92	6.18	1.34E-04	1.79E-02

Interferon Signaling	197	4.12	1.56E-04	1.93E-02
Class I MHC mediated antigen processing &	371	3.06	1.86E-04	2.14E-02
presentation				
Antigen processing-Cross presentation	99	5.74	2.13E-04	2.30E-02
IRF3-mediated induction of type I IFN	13	18.74	4.77E-04	4.85E-02

443 Supplemental Table S15. Disease-based enrichment analysis of 190 up-DEGs associated 444 with severe COVID-19 among *CCR1*+ CD16+monocytes based on the GLAD4U database.

Disease terms	Size	Expect	Enrichment Ratio	P Value	FDR
Infection	643	5.19	5.40	2.90E-13	7.88E-10
Virus Diseases	580	4.68	5.56	1.17E-12	1.59E-09
Inflammation	565	4.56	5.48	4.42E-12	4.01E-09
Hepatitis	253	2.04	7.84	2.45E-10	1.67E-07
Immune System Diseases	806	6.50	3.84	7.35E-09	4.00E-06
Necrosis	371	2.99	5.35	5.79E-08	2.62E-05
Hyperoxia	33	0.27	22.54	2.32E-07	9.03E-05
HIV	862	6.95	3.31	4.60E-07	1.37E-04
Respiratory Tract Infections	281	2.27	5.73	4.85E-07	1.37E-04
virological response	282	2.28	5.71	5.05E-07	1.37E-04
Sexually Transmitted	496	4.00	4.25	5.76E-07	1.42E-04
Diseases					
Encephalitis, Viral	66	0.53	13.15	1.02E-06	2.31E-04
Bacterial Infections	260	2.10	5.72	1.39E-06	2.91E-04
Retroviridae Infections	494	3.99	4.01	2.62E-06	4.87E-04
HIV Infections	495	3.99	4.01	2.69E-06	4.87E-04
Lentivirus Infections	498	4.02	3.98	2.90E-06	4.93E-04
Hepatitis B	190	1.53	6.52	3.39E-06	5.42E-04
Mouth Diseases	246	1.98	5.54	5.25E-06	7.93E-04
Reperfusion Injury	86	0.69	10.09	6.15E-06	8.80E-04
Encephalitis	89	0.72	9.75	7.73E-06	1.05E-03
West Nile Fever	35	0.28	17.71	8.58E-06	1.11E-03

Immunologic Deficiency	500	4.03	3.72	1.36E-05	1.66E-03
Syndromes					
Rhinitis	135	1.09	7.35	1.40E-05	1.66E-03
Tumor Virus Infections	186	1.50	6.00	2.07E-05	2.35E-03
Psoriasis	243	1.96	5.10	2.90E-05	3.16E-03
Autoimmune Diseases	546	4.40	3.41	3.76E-05	3.93E-03
Arthritis, Reactive	78	0.63	9.54	4.00E-05	3.99E-03
Skin and Connective Tissue	617	4.98	3.21	4.11E-05	3.99E-03
Diseases					
Skin Diseases, Viral	85	0.69	8.75	6.50E-05	6.07E-03
Stress	643	5.19	3.08	6.70E-05	6.07E-03
Connective Tissue Diseases	392	3.16	3.79	8.40E-05	7.32E-03
Hepatitis, Chronic	174	1.40	5.70	8.61E-05	7.32E-03
Liver Neoplasms	396	3.19	3.76	9.25E-05	7.61E-03
Periodontitis	91	0.73	8.17	9.52E-05	7.61E-03
Respiratory Syncytial Virus	229	1.85	4.87	1.04E-04	8.09E-03
Infections					
Gram-Positive Bacterial	181	1.46	5.48	1.13E-04	8.56E-03
Infections					
Periodontal Diseases	96	0.77	7.75	1.28E-04	9.41E-03
Dermatitis, Atopic	140	1.13	6.20	1.43E-04	1.02E-02
Dermatomyositis	34	0.27	14.58	1.57E-04	1.09E-02
Hepatitis C	195	1.57	5.09	1.89E-04	1.27E-02
Lipidoses	67	0.54	9.25	2.07E-04	1.31E-02
Pneumonia	109	0.88	6.82	2.57E-04	1.45E-02
Adenocarcinoma	522	4.21	3.09	3.27E-04	1.81E-02
Chondrodysplasia Punctata	83	0.67	7.47	5.62E-04	2.88E-02
Lupus erythematosus	294	2.37	3.79	6.56E-04	3.08E-02
Leukemia	565	4.56	2.85	6.87E-04	3.11E-02
Pharyngeal Neoplasms	137	1.11	5.43	8.66E-04	3.62E-02

Frostbite	6	0.05	41.32	9.50E-04	3.64E-02
Actinomycetales Infections	145	1.17	5.13	1.16E-03	4.00E-02
Measles	62	0.50	8.00	1.58E-03	4.73E-02

446 Supplemental Table S16. 190 up-DEGs associated with severe COVID-19 among CCR1+

447

CD16+monocytes matched in druggable gene categories based on the DGIdb resource

Druggable Gene Category	Matching Gene Count	Matching Gene(s)
Druggable genome	65	AHR, APOBEC3A, ASGR1, C1QB, CD14, CD16
		3, CD300E, CD36, CD53, CD63, CD84, CD99,
		CDKN1A, CTSA, CTSD, CTSL, CXCL8, CYP1B1
		, FKBP5, FOLR3, FPR1, FPR2, GLUL, HBEGF,
		HIF1A, HRH2, HSPA5, ICAM1, IFITM1, IGFB
		P7, IL4R, ISG15, LAIR1, LDHA, LGALS3BP, M
		GST1, NAMPT, PARP9, PGD, PIM1, PIM3, PLB
		D1, PLSCR1, PPIF, PSMA1, PXK, RNASE2, S10
		0A12, S100A8, S100A9, SELL, SERPING1, SGK
		1, SIGLEC1, SLC12A7, SLC25A37, SLC2A3, SM
		PDL3A, TCN2, TNFAIP2, TNFSF10, TXN, TXN
		RD2, UPP1, VCAN
Enzyme	35	AHR, APOBEC3A, ATG12, BLVRB, CTSA, CTS
		D, CTSL, CYP1B1, DYNLL1, GLRX, GLUL, GM
		2A, HIF1A, HSPA5, IFIH1, ISG15, KRTCAP2, N
		CF1, PARP9, PGD, PIM1, PIM3, PXK, S100A8,
		S100A9, SGK1, SMPDL3A, SUMO3, SUPT5H, T
		NFAIP3, UBE2B, UBE2K, UBE2L3, UBE2V2, U
		PP1
Kinase	21	CCNL1, CD163, CD300E, CD63, CDKN1A, GA
		DD45GIP1, HRH2, IFIH1, IRF3, MPLKIP, PIM
		1, PIM3, PXK, RGCC, S100A12, S100A8, S100A
		9, SGK1, SOCS3, STING1, TNFAIP3

Clinically actionable	18	BCL3, CAMTA1, CD36, CDKN1A, CYP1B1, ET
		V6, HIF1A, H2BC12, IRF2, MAML2, NOP10, P
		ER1, PIM1, PRCC, SGK1, SOCS3, STING1, TNF
		AIP3
Transcription factor	14	AHR, ATF3, CAMTA1, CEBPB, CEBPD, ETV6,
		HIF1A, ID1, IF116, IRF2, IRF3, PER1, SCAND1,
		SGK1
Cell surface	8	C1QB, CD36, CD53, CD63, HBEGF, HSPA5,
		ICAM1, VAMP5
Transporter	8	CD36, EMB, HIF1A, HSPA5, SGK1, SLC12A7, S
		LC25A37, SLC2A3
Transcription factor binding	7	AHR, BCL3, HIF1A, ID1, IF116, PIM1, STING1
Drug resistance	6	CDKN1A, ICAM1, LDHA, MGST1, SGK1, UBE2
		В
External side of plasma	6	CD14, CD163, CD36, FLOT1, ICAM1, SLC12A7
membrane		
Protease	5	CTSA, CTSD, CTSL, PSMA1, TNFAIP3
Protease inhibitor	4	APLP2, HSPA5, NAIP, SERPING1
Serine threonine kinase	4	PIM1, PIM3, PXK, SGK1
G protein coupled receptor	3	FPR1, FPR2, HRH2
Nuclear hormone receptor	3	AHR, GADD45GIP1, PER1

Supplemental Table S17. Highly-expressed inflammatory and cytokine genes among ABO+

megakaryocytes

Gene name	T score	Fold change	P value	FDR
ADORA2B	2.80	2.27	5.29E-03	2.227E-02
ADRM1	3.02	1.66	2.72E-03	1.301E-02
AHR	2.52	2.25	1.22E-02	4.349E-02
GNA15	3.49	1.82	5.35E-04	3.461E-03
IRAK2	3.20	2.85	1.48E-03	7.919E-03
KCNA3	3.29	1.89	1.10E-03	6.179E-03

PDGFA	4.26	1.71	2.53E-05	2.666E-04
PTGIR	4.05	1.56	6.18E-05	5.671E-04
SPHK1	3.71	1.57	2.36E-04	1.745E-03
BMP6	2.90	2.44	3.96E-03	1.766E-02
TNFSF4	4.81	2.67	2.18E-06	3.138E-05

452 Supplemental Table S18. Pathway enrichment analysis of 424 highly-expressed genes 453 among ABO+ megakaryocytes.

Pathway name	Gene size	Enrichment	P Value	FDR
		ratio		
Systemic lupus erythematosus	133	4.79	4.55E-07	1.48E-04
Alcoholism	180	4.01	9.82E-07	1.60E-04
Platelet activation	123	3.80	1.42E-04	1.55E-02
SNARE interactions in vesicular	34	6.24	1.10E-03	8.94E-02
transport				
Endocytosis	244	2.43	1.80E-03	1.17E-01
Viral carcinogenesis	201	2.53	2.74E-03	1.28E-01
VEGF signaling pathway	59	4.32	2.52E-03	1.28E-01
Necroptosis	162	2.62	4.83E-03	1.61E-01
Mitophagy	65	3.92	4.11E-03	1.61E-01
Chemokine signaling pathway	189	2.47	4.95E-03	1.61E-01
Transcriptional misregulation in cancer	186	2.28	1.23E-02	3.65E-01
Axon guidance	175	2.18	2.23E-02	6.05E-01
Bacterial invasion of epithelial cells	74	2.87	2.99E-02	6.51E-01
Regulation of actin cytoskeleton	213	1.99	2.88E-02	6.51E-01
Adherens junction	72	2.95	2.70E-02	6.51E-01
Human cytomegalovirus infection	225	1.89	3.97E-02	8.08E-01
Proteoglycans in cancer	201	1.90	4.77E-02	8.64E-01
Tight junction	170	2.00	4.73E-02	8.64E-01

455 456

Supplemental Table S19. Disease-term enrichment analysis of 35 up-DEGs associated with severe COVID-19 among *ABO*+ megakaryocytes based on the GLAD4U database

Term ID	Disease-terms	Size	Expect	Enrichment	P Value
				Ratio	
PA443490	Bernard-Soulier Syndrome	9	0.01	140.31	8.69E-05

PA445644	Shock	367	0.58	8.60	2.59E-04
PA443842	Death	417	0.66	7.57	4.65E-04
PA445846	Thrombocytopenia	96	0.15	19.73	4.67E-04
PA443382	Anoxia	251	0.40	10.06	6.36E-04
PA445457	Pterygium	25	0.04	50.51	7.13E-04
PA165108957	Venous ulcer of leg	26	0.04	48.57	7.71E-04
PA166048906	Blood Platelet Disorders	118	0.19	16.05	8.51E-04
PA444668	Keratitis	31	0.05	40.74	1.10E-03
PA166129556	disease activity score 28	31	0.05	40.74	1.10E-03
	joint in rheumatoid				
	arthritis				
PA443429	Arteritis	34	0.05	37.14	1.32E-03
PA443882	Dermatomyositis	34	0.05	37.14	1.32E-03
PA445850	Thrombosis	141	0.22	13.43	1.42E-03
PA166123766	platelet aggregation	153	0.24	12.38	1.80E-03
PA446220	Abdominal Pain	43	0.07	29.37	2.11E-03
PA445793	Synovitis	47	0.07	26.87	2.51E-03
PA443433	Arthritis, Juvenile	48	0.08	26.31	2.62E-03
	Rheumatoid				
PA445051	Necrosis	371	0.59	6.81	2.68E-03
PA446477	Polymyositis	49	0.08	25.77	2.73E-03
PA166048887	Irritable Bowel Syndrome	50	0.08	25.26	2.84E-03
PA445752	Stress	643	1.02	4.91	3.17E-03
PA445593	Sarcoidosis	56	0.09	22.55	3.55E-03
PA444034	Endocarditis	67	0.11	18.85	5.04E-03
PA443829	Cystic Fibrosis	223	0.35	8.49	5.20E-03
PA445044	Nasal Polyps	75	0.12	16.84	6.27E-03
PA444035	Endocarditis, Bacterial	76	0.12	16.62	6.44E-03
PA445512	Arthritis, Reactive	78	0.12	16.19	6.77E-03
PA446020	Varicose Veins	79	0.13	15.99	6.94E-03

PA165108622	Drug interaction with drug	494	0.78	5.11	7.38E-03
PA165374639	suicide	83	0.13	15.22	7.63E-03
PA446303	Tooth Loss	84	0.13	15.03	7.81E-03
PA444942	Methemoglobinemia	5	0.01	126.28	7.89E-03
PA447296	nondiabetic proteinuric	5	0.01	126.28	7.89E-03
	nephropathy				
PA443474	Bacterial Infections	260	0.41	7.29	7.93E-03
PA445672	Sinusitis	89	0.14	14.19	8.73E-03
PA443690	Charcot-Marie-Tooth	95	0.15	13.29	9.90E-03
	Disease				
PA445382	Polyps	95	0.15	13.29	9.90E-03
PA445296	Periodontal Diseases	96	0.15	13.15	1.01E-02
PA447230	HIV	862	1.37	3.66	1.08E-02
PA165108641	Acatalasia	7	0.01	90.20	1.10E-02
PA165108334	Ulnar neuropathy	8	0.01	78.93	1.26E-02
PA446833	Pouchitis	8	0.01	78.93	1.26E-02
PA445355	Pneumonia	109	0.17	11.59	1.29E-02
PA446540	Cytomegalovirus Retinitis	9	0.01	70.16	1.42E-02
PA447149	Chills	9	0.01	70.16	1.42E-02
PA444231	Fructose Intolerance	10	0.02	63.14	1.57E-02
PA443820	Cryptococcosis	11	0.02	57.40	1.73E-02

458 Supplemental Table S20. 35 up-DEGs significantly associated with severe COVID-19 among
 459 ABO+ megakaryocytes matched in druggable gene categories

Druggable Gene Category	Matching Gene Count	Matching Gene(s)
Druggable genome	11	ACP1, CFLAR, CYB5R3, FKBP8, HSPB1,
		MPIG6B, P2RX1, S100A8, S100A9, SMOX
		, TUBB1
Enzyme	9	ACP1, ATP6V1E1, CYB5R3, ENO1, HK1,
		S100A8, S100A9, SMOX, SUPT4H1
Kinase	5	HCST, HK1, S100A8, S100A9, SKP1

Transporter	4	ATF4, ATP6V1E1, SEC14L1, SLC44A2
Cell surface	2	ENO1, HCST
Clinically actionable	1	МҮН9
Drug resistance	1	CFLAR
External side of plasma	1	P2RX1
membrane		
Ion channel	1	P2RX1
Protease	1	CFLAR
Protein phosphatase	1	ACP1
Transcription factor	1	ATF4

462

Supplemental Table S21. Pathway enrichment analysis of 158 highly-expressed genes among *CXCR6*+ memory CD8+T cells.

Pathway name	Size	Enrichment	P Value	FDR
		Ratio		
Cytokine-cytokine receptor interaction	294	5.65	1.24E-08	4.04E-06
Inflammatory bowel disease (IBD)	65	9.58	3.43E-05	5.58E-03
NF-kappa B signaling pathway	95	5.46	2.14E-03	2.32E-01
Toxoplasmosis	113	4.59	4.54E-03	2.85E-01
Necroptosis	162	3.84	4.55E-03	2.85E-01
Allograft rejection	38	8.19	5.69E-03	2.85E-01
Pyruvate metabolism	39	7.98	6.12E-03	2.85E-01
ABC transporters	44	7.07	8.57E-03	3.49E-01
Apoptosis	136	3.81	9.81E-03	3.55E-01
Intestinal immune network for IgA production	49	6.35	1.15E-02	3.76E-01
Autoimmune thyroid disease	53	5.87	1.43E-02	4.23E-01
Chagas disease (American trypanosomiasis)	102	4.07	1.66E-02	4.51E-01
Human cytomegalovirus infection	225	2.77	2.09E-02	5.25E-01
Kaposi sarcoma-associated herpesvirus infection	186	2.79	3.32E-02	6.83E-01
Citrate cycle (TCA cycle)	30	6.92	3.35E-02	6.83E-01

Chemokine signaling pathway	189	2.74	3.52E-02	6.83E-01
Circadian rhythm	31	6.69	3.56E-02	6.83E-01
Measles	132	3.14	3.81E-02	6.85E-01
Apoptosis	33	6.29	3.99E-02	6.85E-01
Phenylalanine, tyrosine and tryptophan biosynthesis	5	20.75	4.73E-02	7.71E-01

464 Supplemental Table S22. GO-terms enrichment analysis of 108 up-DEGs associated with 465 COVID-19 among *CXCR6*+ memory CD8+T cells.

GO-terms	Size	Enrichment	P Value	FDR
		ratio		
Immune response-activating cell surface receptor signaling pathway	300	6.79	6.30E-07	2.83E-03
Positive regulation of immune system process	979	3.59	9.22E-07	2.83E-03
Immune response-activating signal transduction	454	5.30	9.34E-07	2.83E-03
Immune response-regulating cell surface receptor signaling pathway	330	6.17	1.60E-06	3.54E-03
Immune response-regulating signaling pathway	485	4.96	1.95E-06	3.54E-03
Post-translational protein modification	360	5.66	3.71E-06	4.83E-03
Regulation of immune system process	1400	2.91	3.72E-06	4.83E-03
Positive regulation of immune response	706	3.93	5.21E-06	5.63E-03
Activation of immune response	534	4.51	5.58E-06	5.63E-03
Leukocyte differentiation	496	4.48	1.41E-05	1.28E-02
Hemopoiesis	791	3.51	2.01E-05	1.66E-02
Hematopoietic or lymphoid organ development	833	3.33	3.67E-05	2.78E-02
Regulation of hemopoiesis	389	4.76	4.64E-05	3.25E-02
Immune response-regulating cell surface receptor signaling pathway involved in phagocytosis	76	12.18	5.61E-05	3.28E-02
Fc-gamma receptor signaling pathway involved in phagocytosis	76	12.18	5.61E-05	3.28E-02
Immune response	1919	2.32	5.76E-05	3.28E-02
Antigen receptor-mediated signaling pathway	184	7.04	6.16E-05	3.29E-02
Fc-gamma receptor signaling pathway	79	11.72	6.75E-05	3.32E-02
Immune system development	881	3.15	6.94E-05	3.32E-02
Fc receptor mediated stimulatory signaling pathway	81	11.43	7.61E-05	3.46E-02

Regulation of leukocyte differentiation	263	5.63	8.77E-05	3.80E-02
Regulation of immune response	909	3.06	9.86E-05	4.07E-02

467 **References**

- M. Ghoussaini *et al.*, Open Targets Genetics: systematic identification of trait-associated
 genes using large-scale genetics and functional genomics. *Nucleic Acids Res* 49, D1311 d1320 (2021).
- 471 2. Y. Ma *et al.*, Integrative Genomics Analysis Reveals a 21q22.11 Locus Contributing Risk
 472 to COVID-19. *Hum Mol Genet*, (2021).
- 473 3. E. Pairo-Castineira *et al.*, Genetic mechanisms of critical illness in COVID-19. *Nature*474 **591**, 92-98 (2021).
- 475 4. C. A. de Leeuw, J. M. Mooij, T. Heskes, D. Posthuma, MAGMA: generalized gene-set 476 analysis of GWAS data. *PLoS Comput Biol* **11**, e1004219 (2015).
- 477 5. A. Auton *et al.*, A global reference for human genetic variation. *Nature* **526**, 68-74 (2015).
- 478